secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2022-07-11T23:59:59+00:00
Accession:  0001140361-22-025724
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva completes acquisition of Entasis Therapeutics for $2.20/share, total ~$42.4M
--------------------------------------------------------------------------------

- Acquisition closed on July 11, 2022; Entasis becomes wholly-owned subsidiary of Innoviva.
- Total consideration of approximately $42.4M paid for all outstanding shares tendered at $2.20 per share.
- Entasis' pipeline includes SUL-DUR for Gram-negative bacteria; NDA submission planned for Q3 2022.
- Entasis common stock to be delisted from Nasdaq Global Market following acquisition.
- Innoviva funded the purchase from its own resources; deal creates new growth channel and diversifies revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000114036122025724/0001140361-22-025724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000114036122025724/ny20004305x11_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-025724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer